Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Essential Thrombocythemia
- JAK2 Mutation
- Myeloproliferative Neoplasm
- Polycythemia Vera
- Primary Myelofibrosis
- Venous Thromboembolism
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04243122
- Collaborators
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
- the Association médicale universitaire de l'Hôpital Montfort (AMUHM)
- Canadian Society of Hematology
- Investigators
- Principal Investigator: Aurelien Delluc, MD, PhD The Ottawa Hospital Principal Investigator: Miriam Kimpton, MD The Ottawa Hospital